First filing for Kowa's peretinoin, for recurrent liver cancer
This article was originally published in Scrip
Executive Summary
Kowa has filed an application in Japan for the approval of peretinoin (NIK-333) for the suppression of recurrence of previously treated hepatocellular carcinoma (HCC) in hepatitis C patients.